Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Xibrom bromfenac: Phase IV data

In a Phase IV trial in 122 patients with acute pseudophakic CME following cataract

Read the full 148 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE